Form 6-K Summary
Registrant: NLS Pharmaceutics Ltd. The supplied metadata identifies Newcelx Ltd., but the filing names NLS Pharmaceutics Ltd.
Reporting period: April 2022, Report No. 3; filed April 14, 2022.
Business Context and Transaction
On April 13, 2022, NLS Pharmaceutics entered into a securities purchase agreement for a registered direct offering expected to close on or about April 25, 2022, subject to customary conditions. The financing is intended primarily to support development of Quilience® (Mazindol ER) for narcolepsy, business development and licensing activities, and general corporate purposes.
Financial and Capital Markets Details
- 3,015,384 common shares will be issued at $1.04 per share.
- Pre-funded warrants to purchase up to 1,184,616 common shares will be issued at $1.04 less CHF 0.02 per warrant. They are immediately exercisable at CHF 0.02 per share.
- Investors will also receive unregistered warrants to purchase up to 3,150,000 common shares at an exercise price of $1.04 per share. These warrants become exercisable six months after issuance and expire five and a half years after issuance.
- Gross proceeds are expected to be approximately $4.368 million, assuming full exercise of the pre-funded warrants. The filing does not provide a clear net-proceeds amount.
- The placement agent will receive a cash fee equal to 7.0% of gross proceeds, excluding securities purchased by Chairman Ronald Hafner.
- Chairman Ronald Hafner agreed to purchase 95,984 common shares.
- Management expects the financing to restore compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), upon closing.
Material Changes, Outlook, and Risks
- The transaction will increase outstanding shares and may result in additional dilution if the warrants are exercised.
- The company agreed, subject to customary exceptions, not to issue or announce proposed issuances of common shares or equivalents for 60 days after closing.
- The offering was not yet closed as of the filing date; proceeds, compliance restoration, and financing-related benefits therefore remained conditional.
- Common warrants and their underlying shares are unregistered and may be resold in the United States only pursuant to an effective registration statement or an applicable exemption.
- The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity figures for the reporting period.
- The securities purchase agreement, placement agent agreement, warrant forms, legal opinions, and related press release were filed as exhibits.
Key Facts for Investors to Verify
- Whether the offering closed on or about April 25, 2022 and the actual gross and net proceeds received.
- Whether the company subsequently regained compliance with Nasdaq’s minimum stockholders’ equity requirement.
- The number of common shares outstanding after the offering and the potential dilution from all warrants.
- The terms, registration status, and resale limitations applicable to the common warrants and underlying shares.
- How the proceeds were allocated among Quilience development, licensing and business development, and general corporate purposes.